1 March 2016 - A new leukaemia drug viewed by industry experts as a future blockbuster has been rejected by Britain's healthcare cost-effectiveness agency NICE, which said it could not be confident the medicine represented an effective use of resources.

For more details, go to: http://www.reuters.com/article/us-abbvie-johnson-johnson-britain-idUSKCN0W400L